We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Boston Scientific (BSX) Registers a Bigger Fall Than the Market: Important Facts to Note
Read MoreHide Full Article
In the latest close session, Boston Scientific (BSX - Free Report) was down 2.5% at $44.46. The stock trailed the S&P 500, which registered a daily loss of 0.1%. Elsewhere, the Dow gained 0.35%, while the tech-heavy Nasdaq lost 0.43%.
Shares of the medical device manufacturer witnessed a loss of 20.89% over the previous month, trailing the performance of the Medical sector with its gain of 1.97%, and the S&P 500's loss of 1.34%.
Market participants will be closely following the financial results of Boston Scientific in its upcoming release. It is anticipated that the company will report an EPS of $0.83, marking a 10.67% rise compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $5.39 billion, up 6.54% from the prior-year quarter.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $3.36 per share and a revenue of $21.61 billion, signifying shifts of +9.8% and +7.65%, respectively, from the last year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Boston Scientific. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.51% lower. As of now, Boston Scientific holds a Zacks Rank of #4 (Sell).
Valuation is also important, so investors should note that Boston Scientific has a Forward P/E ratio of 13.58 right now. Its industry sports an average Forward P/E of 17.47, so one might conclude that Boston Scientific is trading at a discount comparatively.
Meanwhile, BSX's PEG ratio is currently 0.87. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. BSX's industry had an average PEG ratio of 1.56 as of yesterday's close.
The Medical - Products industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 175, placing it within the bottom 29% of over 250 industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Boston Scientific (BSX) Registers a Bigger Fall Than the Market: Important Facts to Note
In the latest close session, Boston Scientific (BSX - Free Report) was down 2.5% at $44.46. The stock trailed the S&P 500, which registered a daily loss of 0.1%. Elsewhere, the Dow gained 0.35%, while the tech-heavy Nasdaq lost 0.43%.
Shares of the medical device manufacturer witnessed a loss of 20.89% over the previous month, trailing the performance of the Medical sector with its gain of 1.97%, and the S&P 500's loss of 1.34%.
Market participants will be closely following the financial results of Boston Scientific in its upcoming release. It is anticipated that the company will report an EPS of $0.83, marking a 10.67% rise compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $5.39 billion, up 6.54% from the prior-year quarter.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $3.36 per share and a revenue of $21.61 billion, signifying shifts of +9.8% and +7.65%, respectively, from the last year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Boston Scientific. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.51% lower. As of now, Boston Scientific holds a Zacks Rank of #4 (Sell).
Valuation is also important, so investors should note that Boston Scientific has a Forward P/E ratio of 13.58 right now. Its industry sports an average Forward P/E of 17.47, so one might conclude that Boston Scientific is trading at a discount comparatively.
Meanwhile, BSX's PEG ratio is currently 0.87. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. BSX's industry had an average PEG ratio of 1.56 as of yesterday's close.
The Medical - Products industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 175, placing it within the bottom 29% of over 250 industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.